PelaiaCPaolettiGPuggioniF, et alInterleukin-5 in the pathophysiology of severe asthma. Front Physiol. 2019;10:1514. doi:10.3389/fphys.2019.01514
2.
KimDKobayashiTVoisinB, et alTargeted therapy guided by single-cell transcriptomic analysis in drug-induced hypersensitivity syndrome: a case report.Nat Med. 2020;26(2):236-243. doi:10.1038/s41591-019-0733-7
3.
RubinLTalmonARibakY, et alNovel targeted inhibition of the IL-5 axis for drug reaction with eosinophilia and systemic symptoms syndrome. Front Immunol. 2023;14:1134178. doi:10.3389/fimmu.2023.1134178
4.
DubinDPYasskyDPoplauskyDYoungJNTanKJGulatiN. Dupilumab to treat drug reaction with eosinophilia and systemic symptoms: a case series. J Allergy Clin Immunol Pract. 2023;11(12):3789-3791. doi:10.1016/j.jaip.2023.08.028
5.
Nakamura-NishimuraYMiyagawaFMiyashitaKOmmoriRAzukizawaHAsadaH. Serum thymus and activation-regulated chemokine is associated with the severity of drug reaction with eosinophilia and systemic symptoms/drug-induced hypersensitivity syndrome. Br J Dermatol. 2018;178(6):1430-1432. doi:10.1111/bjd.16132
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
